pharmaceutical investing Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients
LITHIUM AFRICA CORP. ANNOUNCES UPSIZE IN PRIVATE PLACEMENT TO C$8.5M WITH LEAD ORDER FROM PURPOSE GLOBAL RESOURCE FUND
